Cogent Biosciences (COGT) has launched an underwritten public offering of $150 million in common stock. The company plans to use the net proceeds to advance development, regulatory, and commercial preparation efforts for bezuclastinib and other product candidates, along with supporting working capital and general corporate needs.
All securities in the offering are being offered by Cogent Communications Holdings, Inc. (CCOI)
The offering is managed jointly by J.P. Morgan, Leerink Partners, and Guggenheim Securities, with LifeSci Capital serving as lead manager.
